Pierluigi Selvaggi

1 month ago | nature.com | Alessio Giacomel |Daniel Martins |Oliver Howes |Pierluigi Selvaggi |Federico Turkheimer |Ottavia Dipasquale | +1 more

AbstractMolecular neuroimaging techniques, like PET and SPECT, offer invaluable insights into the brain’s in-vivo biology and its dysfunction in neuropsychiatric patients. However, the transition of molecular neuroimaging into diagnostics and precision medicine has been limited to a few clinical applications, hindered by issues like practical feasibility, high costs, and high between-subject heterogeneity of neuroimaging measures.